Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1663-1676

  Absar, Shahriar ^a   Nahar, Kamrun ^a   Kwon, Young Min ^a,b   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

localized fibrinolysis; peptide modified liposomes; protein delivery; targeted delivery; tissue plasminogen activator

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; LIPOSOME; NANOCARRIER; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BLEEDING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; ENTRAPMENT EFFICIENCY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; INFERIOR CAVA VEIN; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; ZETA POTENTIAL;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENTS; HALF-LIFE; HEMORRHAGE; HUMANS; LIPOSOMES; MALE; NANOPARTICLES; PEPTIDES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84877765400     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1011-x     Document Type: Article

References (43)

1. Lovlien M, Johansson I, Hole T, Schei B. Early warning signs of an acute myocardial infarction and their influence on symptoms during the acute phase, with comparisons by gender. Gend Med. 2009;6:444-53.
2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
3. Leach JK, O'Rear EA, Patterson E, Miao Y, Johnson AE. Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase. Thromb Haemost. 2003;90:64-70.
4. Chung TW, Wang SS, Tsai WJ. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co- glycolide) (PLGA) nanoparticles. Biomaterials. 2008;29:228-37.
5. Bode C, Runge MS, Haber E. Future directions in plasminogen activator therapy. Clin Cardiol. 1990;13:375-81.
6. Collen D, Stump DC, Gold HK. Thrombolytic therapy. Annu Rev Med. 1988;39:405-23.
7. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol. 1996;51:255-60.
8. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood. 1986;68:275-80.
9. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation. 1997;96:761-8.
10. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med. 1997;337:1118-23.
11. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke. 2001;32:748-52.
12. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci U S A. 1987;84:7659-62.
13. Berger Jr H, Pizzo SV. Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. Blood. 1988;71:1641-7.
14. Lippi G, Mattiuzzi C, Favaloro EJ. Novel and emerging therapies: thrombus-targeted fibrinolysis. Semin Thromb Hemost. 2012. doi: 10.1055/s-0032-1328935
15. Bos R, Nieuwenhuizen W. The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made. Biotherapy. 1992;5:187-99.
16. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256-65.
17. Piras AM, Chiellini F, Fiumi C, Bartoli C, Chiellini E, Fiorentino B, et al. A new biocompatible nanoparticle delivery system for the release of fibrinolytic drugs. Int J Pharm. 2008;357:260-71.
18. Park Y, Liang J, Yang Z, Yang VC. Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel. J Control Release. 2001;75:37-44.
19. Liang JF, Li YT, Song H, Park YJ, Naik SS, Yang VC. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. J Control Release. 2002;78:67-79.
20. Absar S, Choi S, Yang VC, Kwon YM. Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis. J Control Release. 2012;157:46-54.
21. Absar S, Choi S, Ahsan F, Cobos E, Yang VC, Kwon YM. Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: an approach for localized thrombolysis. Thromb Res. 2012. doi: 10.1016/j.thromres.2012.11.030.
22. Ware S, Donahue JP, Hawiger J, Anderson WF. Structure of the fibrinogen gamma-chain integrin binding and factor XIIIa cross-linking sites obtained through carrier protein driven crystallization. Protein Sci. 1999;8:2663-71.
23. Naik SS, Liang JF, Park YJ, Lee WK, Yang VC. Application of "ATTEMPTS" for drug delivery. J Control Release. 2005;101:35-45.
24. Kim JY, Kim JK, Park JS, Byun Y, Kim CK. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials. 2009;30:5751-6.
25. Liang JF, Song H, Li YT, Yang VC. A novel heparin/protamine-based pro-drug type delivery system for protease drugs. J Pharm Sci. 2000;89:664-73.
26. Gupta AS, Huang G, Lestini BJ, Sagnella S, Kottke-Marchant K, Marchant RE. RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system. Thromb Haemost. 2005;93:106-14.
27. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. Plast Reconstr Surg. 2006;118:147e-59.
28. Downing LJ, Strieter RM, Kadell AM, Wilke CA, Greenfield LJ, Wakefield TW. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis. J Vasc Surg. 1998;28:848-54.
29. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990;60:269-80.
30. Natarajan JV, Chattopadhyay S, Ang M, Darwitan A, Foo S, Zhen M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PLoS One. 2011;6:e24513.
31. Atyabi F, Farkhondehfai A, Esmaeili F, Dinarvand R. Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice. Acta Pharm. 2009;59:133-44.
32. Bai S, Ahsan F. Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism. J Pharm Sci. 2010;99:4554-64.
33. Le UM, Cui Z. Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm. 2006;312:105-12.
34. Toongsuwan S, Li LC, Erickson BK, Chang HC. Formulation and characterization of bupivacaine lipospheres. Int J Pharm. 2004;280:57-65.
35. Gupta Y, Jain A, Jain P, Jain SK. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J Drug Target. 2007;15:231-40.
36. Heeremans JL, Gerritsen HR, Meusen SP, Mijnheer FW, Gangaram Panday RS, Prevost R, et al. The preparation of tissue-type Plasminogen Activator (t-PA) containing liposomes: entrapment efficiency and ultracentrifugation damage. J Drug Target. 1995;3:301-10.
37. Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest. 1984;73:1731-9.
38. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90:667-80.
39. Nguyen PD, O'Rear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. Circ Res. 1990;66:875-8.
40. Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, Kluft C, et al. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb Haemost. 1995;73:488-94.
41. Perkins WR, Vaughan DE, Plavin SR, Daley WL, Rauch J, Lee L, et al. Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model. Thromb Haemost. 1997;77:1174-8.
42. Parente RA, Nadasdi L, Subbarao NK, Szoka Jr FC. Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. Biochemistry. 1990;29:8713-9.
43. Unstable angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction. London; 2010.